NEW YORK — Eli Lilly and Co. says it stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers.
The company stopped testing LY2886721 because of abnormal results in liver biochemical tests. Lilly says the results were found as part of routine monitoring and it will continue to monitor all patients.
The Indianapolis company will evaluate data from the trial before deciding on the next steps for the drug. Lilly says it may continue development of similar drugs. Lilly will take a charge related to stopping the trial, but it won't affect its full-year guidance.
The company is also running late-stage studies on the drug solanezumab as a treatment for Alzheimer's disease.
Eli Lilly shares fell 66 cents to $51.19 in after-hours trading.
